Biosimilars: What Have We Learned?

Abstract

Get full access to this article

View all access options for this article.

References

Association of Diabetes Care and Education Specialists. Resources for people living with diabetes. Accessed December 11, 2021. https://www.diabeteseducator.org/living-with-diabetes

Blevins

Barve

Raiter

, et al. Efficacy and safety of MYL-150-1D vs insulin glargline in people with type 1 diabetes mellitus: results of the INSTRIDE 3 phase 3 switch study. Diabetes Obes Metab. 2020;22:365-372.

Blevins

Barve

Sun

Ankersen

. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: results of the INSTRIDE 1 phase III study. Diabetes Obes Metab. 2018;20:1944-1950.

Blevins

Barve

Sun

, et al. Efficacy and safety of MYL-150-1D vs insulin glargine in patients with type 2 diabetes after 24 weeks: results of the phase III INSTRIDE 2 study. Diabetes Obes Metabl. 2019;21:129-135.

Cardional Health. Biosimilar interchangeability laws by state. Accessed December 11, 2021. https://www.cardin-alhealth.com/biosimilars

Food and Drug Administration. Biosimilars. Accessed December 11, 2021. http://www.fda.gov/biosimlars

Food and Drug Administration. Biosimilars action plan: balancing innovation and competition. July 2018. Accessed January 25, 2022. https://www.fda.gov/media/114574/download

Food and Drug Administration. Drug development process. Accessed December 13, 2021. https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-devel-opment-process

Kinch

. An overview of FDA-approved biologics medicines. Drug Discov Today. 2015;20(4):393-398.

10.

Triplitt

Hinnen

Valentine

. How similar are biosimi-lars? What do clinicians need to know about biosimilar and follow-on insulins? Clin Diabetes. 2017;35(4):209-216.

11.

US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Cener for Biologics Evaluation and Research. Biosimilars, Revision 2, Sep. 2021. Available at: www.fda.gov/regulatory-information/search-fda-guidance-docu-ments/questions-and-answers-biosimilar-development-and-bpci-act-guidance-industry

12.

Viatris. Viatris and Biocon Biologics announce launch of interchangeable SEMGLEE (insulin glargine-yfgn) injection and insulin glargine (insulin glargine-yfgn) injection. November 16, 2021. Accessed June 27, 2022. https://www.prnewswire.com/news-releases/viatris-and-biocon-bi-ologics-announce-launch-of-interchangeable-semglee-insulin-glargine-yfgn-injection-and-insulin-glargine-insulin-glargine-yfgn-injection-301425151.html